
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRB5
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Chime Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
SunRock Biopharma, Chime Biologics Collaborate on Anti-CCR9 Antibody SRB5 Development
Details : The collaboration aims to advance SRB5, an unconjugated antibody targeting CCR9, for the treatment of inflammatory bowel disease (IBD).
Product Name : SRB5
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 20, 2025
Lead Product(s) : SRB5
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Chime Biologics
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody
Details : Debiopharm has exercised its option to license SRB21, SunRock Biopharma's bispecific antibody, which targets both HER2 and HER3 human epidermal growth factor receptors.
Product Name : SRB21
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 30, 2025
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRB19
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Debiopharm Extends Partnership with SunRock for HER3 Targeted Antibody
Details : SunRock will develop SRB19, a HER3-EGFR bispecific antibody-drug conjugate for head and neck cancer, using Debiopharm's Multilink technology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : SRB19
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody dr...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRB22
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ellipses Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : SRB22
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ellipses Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
